TET1 and metabolic dysfunction-associated steatotic liver disease: Furthermore, TET1 i significantly inhibited TET1 and CD36 protein expression levels (Fig. 7M,N), strongly supporting the TET1 i-mediated CD36 downregulation contributing to the improved MASLD phenotypes.